September PBS listings climb to eight

Six companies have expanded their drugs on the PBS this month, with MSD securing a long-awaited multi-indication listing for its blockbuster while two companies scored a double win.

GSK’s Nucala 100 mg/mL pre-filled pen, previously reimbursed for certain patients with (uncontrolled) asthma and chronic rhinosinusitis with nasal polyps has become the first biologic treatment to be added to the scheme for adults living with uncontrolled chronic obstructive pulmonary disease (COPD).

Welcoming the news, GSK Australia Vice President and General Manager, Andrew Thomas, said that the company “is committed to improving outcomes for people living with respiratory diseases”.

To see the whole article please log in.

Tiffany Walker

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here